纳米药物辅助基于免疫原性细胞死亡（ICD）的抗癌疗法。

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-03-29 DOI:10.1016/j.trecan.2024.03.003

Robin Demuynck, Yanou Engelen, André G Skirtach, Stefaan C De Smedt, Ine Lentacker, Dmitri V Krysko

{"title":"纳米药物辅助基于免疫原性细胞死亡（ICD）的抗癌疗法。","authors":"Robin Demuynck, Yanou Engelen, André G Skirtach, Stefaan C De Smedt, Ine Lentacker, Dmitri V Krysko","doi":"10.1016/j.trecan.2024.03.003","DOIUrl":null,"url":null,"abstract":"Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"486-489"},"PeriodicalIF":14.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy.\",\"authors\":\"Robin Demuynck, Yanou Engelen, André G Skirtach, Stefaan C De Smedt, Ine Lentacker, Dmitri V Krysko\",\"doi\":\"10.1016/j.trecan.2024.03.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.\",\"PeriodicalId\":23336,\"journal\":{\"name\":\"Trends in cancer\",\"volume\":\" \",\"pages\":\"486-489\"},\"PeriodicalIF\":14.3000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.trecan.2024.03.003\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.trecan.2024.03.003","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

免疫性细胞死亡（ICD）正在成为抗肿瘤疗法的一个关键组成部分，它能利用患者的免疫系统来对抗癌症。近年来，人们为改进基于免疫细胞死亡的疗法做出了许多努力。在此，我们将讨论基于纳米材料的策略如何提高 ICD 的疗效，并强调其优势和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy.

Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.